Critical

Serotonin syndrome & neuroleptic malignant syndrome

SS / NMS · Critical Care / ICU
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Serotonin syndrome and neuroleptic malignant syndrome are drug-induced hyperthermic emergencies with autonomic instability, altered mental state and neuromuscular changes. Distinguishing them (rapid onset with clonus and hyperreflexia versus subacute onset with lead-pipe rigidity and bradyreflexia) guides specific therapy; both need aggressive supportive cooling.

Red flags

  • Core temperature above 41 degrees
  • Severe rigidity with rising CK
  • Haemodynamic instability / arrhythmia
  • Seizures or coma
  • Rhabdomyolysis with hyperkalaemia and AKI

Assessment

Differential diagnosis

  • Serotonin syndrome
  • Neuroleptic malignant syndrome
  • Malignant hyperthermia
  • Anticholinergic toxicity
  • Sympathomimetic toxicity
  • Meningoencephalitis / sepsis
  • Thyroid storm

Investigations

  • Medication and overdose history
  • Creatine kinase (markedly raised in NMS)
  • Core temperature
  • Renal function and electrolytes
  • ABG and lactate
  • Septic/CNS screen to exclude mimics

Management

  • Stop the offending drug immediately (serotonergic agents for SS; dopamine antagonists / withdrawn dopamine agonists for NMS)
  • Distinguish the syndrome: SS onset within hours with clonus, hyperreflexia, agitation; NMS onset over days with lead-pipe rigidity, bradyreflexia, very high CK
  • Provide aggressive supportive care: oxygen, IV fluids, continuous monitoring
  • Control hyperthermia with active external cooling; treat temperature above 41 degrees as an emergency
  • Control agitation and muscle hyperactivity with benzodiazepines
  • For severe hyperthermia or rigidity, consider sedation, paralysis (non-depolarising) and intubation to abolish muscle heat production
  • For serotonin syndrome, give cyproheptadine as a serotonin antagonist
  • For NMS, consider dantrolene and/or bromocriptine as specific therapy
  • Avoid antipyretics (ineffective - heat is from muscle activity) and avoid suxamethonium (hyperkalaemia with rhabdomyolysis)
  • Treat rhabdomyolysis with fluids and monitor for AKI and hyperkalaemia
  • Manage autonomic instability (labile BP/HR) with short-acting titratable agents
  • Monitor until resolution, which is faster for SS (usually 24 h) than NMS (days to weeks)

Drugs & doses

Lorazepam/diazepam IV titrated for agitation and rigidity
Cyproheptadine 12 mg PO/NG then 2 mg 2 hourly (serotonin syndrome)
Dantrolene 1-2.5 mg/kg IV (severe NMS/hyperthermia)
Bromocriptine 2.5 mg PO/NG 8 hourly (NMS)
Non-depolarising paralysis (e.g. rocuronium) for refractory hyperthermia - AVOID suxamethonium

Disposition

ICU with active cooling and toxicology/poisons centre advice; monitor CK and renal function closely.

Complications & pitfalls

  • Rhabdomyolysis and AKI
  • Hyperthermic multi-organ failure
  • DIC
  • Arrhythmia and cardiovascular collapse
  • Aspiration
  • Death

Exam pearls

  • Clonus and hyperreflexia point to serotonin syndrome; lead-pipe rigidity with very high CK points to NMS
  • Heat comes from muscle activity - benzodiazepines, paralysis and cooling work; antipyretics do not
  • Avoid suxamethonium in rhabdomyolysis-prone patients due to hyperkalaemia risk
  • Severe hyperthermia above 41 degrees is immediately life-threatening - paralyse and intubate early

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.